WORCESTER BUSINESS JOURNAL - The privately held company has raised $60 million in capital, with its largest investor Romulus Capital in Boston, Gaur said. Friday’s ribbon cutting at its new facility doubled as Allurion’s 10th anniversary, and Gaur used the occasion to look both back and ahead. “In the next 10 years,” Gaur said, “we’ll ask, how can we have (customers) with us for not just four years but for decades?” With U.S. Food and Drug Administration approval expected next year and a market debut in late 2020, Gaur thinks the company can hit the 200,000-a-year figure in the next four or five years.